Abstract
In this issue of Blood, Ross et al report the TWISTER study in which imatinib was stopped in chronic myeloid leukemia patients with undetectable minimal residual disease (UMRD) and show that >40% remained off treatment without recurrence at 2 years.1 © 2013 by The American Society of Hematology.
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for freeCite
CITATION STYLE
APA
Apperley, J. F. (2013). TWIST it but don’t spin it. Blood, 122(4), 470–471. https://doi.org/10.1182/blood-2013-06-506097
Readers' Seniority
Readers' Discipline
